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Summary.-The antitumour activities of N-methylformamide, N-ethylformamide
and formamide against a number of murine tumours in vivo (Sarcoma 180, M5076
ovarian sarcoma and TLX5 lymphoma) have been estimated. In all cases N-methyl-
formamide had significant activity, formamide had marginal or no activity and
N-ethylformamide had no significant activity. N-methylformamide and N-ethyl-
formamide were equitoxic to the TLX5 lymphoma in vitro. Formamide was found
as a metabolite in the plasma and urine of animals given N-methylformamide and
N-ethylformamide, but excretion profiles do not support the hypothesis that
formamide is an active antitumour species formed from N-alkylformamides. No
appreciable metabolism of N-methylformamide occurred under a variety of
conditions with liver preparations in vitro. N-methylformamide, but not N-ethyl-
formamide or formamide, reduced liver soluble non-protein thiols by 59.8O 1 h after
administration of an effective antitumour dose.
THE ANTITUMO-UR ACTIVITY of N-
methylformamide (NMF, HCONH CH3)
against murine tumours was first des-
cribed in the early 1 950s (Clarke et al.,
1953; Furst et al., 1955). In structure
activity studies of almost 150 forma-
mides and related compounds, NMF
was found to be the most potent inhibitor
of tumour growth and even small changes
in molecular structure, such as substitu-
tion of the methyl group with an ethyl
group, completely abolished activity. For-
mamide (HCONH2) and dimethylforma-
mide (HCONMe2), however, showed
marginal activity. Early studies on the
mechanism of action of NMF suggested
that it interferes with nucleic acid base
synthesis (Clarke et al., 1953 Skipper
et al., 1955: Wheeler & Grammer, 1960;
Eidinoff et al., 1961; Sartorelli & Le Page,
1958; Morrison & Higgins, 1955), though
it appeared to stimulate the incorporation
of formate into nucleic acids in the liver
(Barclay & Garfinkel, 1954), an organ to
which it is toxic.
The hepatotoxicity of NMF reported
in an early clinical trial in man (Myers
et al., 1956) was considered to be an
unacceptable side effect, and interest in
its clinical use and pharmacology was
largely lost. Recently, NMF has been
found to be active against 3 human
tumour xenografts in mice (Wolpert,
personal communication) and there is
renewe(d interest in its potential for
clinical use in man. W!e were particularly
interested in the observation that the
substitution of an N-ethyl group in the
formamide molecule led to a considerable
reduction in activity, an observation
also made regarding the antitumour
activity of three other types of anti-
tumour agent which we have been investi-
gating, namely hexamethylmelamine,
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aryldimethyltriazenes and procarbazine
(Hickman, 1978). Our studies on the
mechanism of action of these compounds,
and in particular of their fate upon
metabolism by the host, have centred
upon the role and fate of the N-methyl
group (Gescher et al., 1979; Gescher &
Raymont, 1981). It was considered that
a study of NMF, a simple and stable
molecule compared to chemically labile
triazenes and hydrazines, may contribute
to an understanding of the mechanism
of action of agents which require an
N-methyl group for activity. Accordingly,
we have studied the antitumour activity
of NMF and certain analogues against
3 murine tumours, Sarcoma 180, on
which the original data was reported
(Clarke et al., 1953), the M5076 ovarian
sarcoma (previously classified as a
carcinoma but recently reclassified
(Talmadge et al., 1981)), a tumour par-
ticularly sensitive to hexamethylmela-
mine (Simpson-Herren et al., 1979) and
the TLX5 lymphoma, the tumour on
which our other studies of the drugs
containing N-methyl group have been
made (Gescher et al., 1981). Additionally,
we report here on both in vivo and in
vitro studies of the metabolism of N-
alkylformamides, in particular, attempts
to identify and quantitate metabolites
resulting from their oxidative dealkyla-
tion. These studies are related to both
the possible mechanism of cytotoxicity of
NMF and to a possible biochemical
explanation of the hepatotoxic lesions
found in animals and man.
MATERIALS AND METHODS
The derivatives of formamide used in
this study were all commercially available
(Aldrich Chemicals, Gillingham) except N-
ethylformamide (NEF) which was synthesized
in our laboratories by Dr R. J. Simmonds
according to published methods (Saegusa
et al., 1969). Drugs were administered i.p.
or s.c. dissolved in sterile saline. Nicotina-
mide adenine diphosphonucleotide and glu-
cose-6-phosphate were purchased from Sigma
(U.K.) Ltd. Media and serum were purchased
from Gibco (Glasgow) Ltd.
Aitditumour assays
M5076 ovarian sarcoma. A suspension
prepared by homogenization in saline of 106
cells from a routine passage, grown as a
solid s.c. tumour in female BDF1 mice, was
injected i.m. into the left lhind leg of groups
of 10 female BDF1 mice (18-23 g). Drugs
were administered i.p. for up to 17 days,
(i.e. approximately half the life-span of the
control tumour-bearing animals). Mean tu-
mour volumes were measured by calipers
every 4th day from Day 12 until death, and
the mean tumour-volume index calculated
by the standard method (Geran et al., 1972).
Sarcoma 180.-A suspension of 106 cells,
from a routine passage of the tumour as an
ascites in female BDF1 mice, was injected
i.m. into the left hind leg of 18-23 g
female BDF1 mice. Drugs were administered
i.p. for up to 9 days. Mean tumour volumes
Awere measured by calipers on Days 6, 10,
13 and 16 and the mean tumour-volume
index calculated by the standard method
(Geran et al., 1972).
TLX5 lymphomas.-Two TLX5 lympho-
mas were used, one with sensitivity to DTIC
(5 - (3,3 - Dimethyl- 1 -triazeno)imidazole - 4-
carboxamide) and procarbazine (1-methyl-
2 - p - (isopropylcarbamoyl)benzylhydrazine)
known as the TLX5S and one with resistance
to these drugs, known as TLX5R (Hickman,
1978; Gescher et al., 1981). 105 TLX5 cells
from routine passage as ascites in male
CBA/CA mice were injected s.c. into the
inguinal region of female CBA/CA mice
(18-23 g). Drugs were administered i.p.
up to Day 7 and the survival time of treated
animals compared to untreated controls, a
protocol used by others for this tumour
(Connors & Hare, 1975).
TLX5 lymphoma IN VITRO-IN VIVO assay.
106 cells/ml from a routine passage were
incubated in 2 ml of 6 parts of RPMI 1640
medium and 4 parts of horse serum with
drugs for 2 h. 105 cells were injected i.p.
into 20 g female CBA mice and the survival
time of animals receiving treated cells was
compared to those receiving untreated cells.
IN VITRO metabolism. Livers of male
CBA/CA or BALB/c mice (20-25 g) were
homogenized in 0-25M sucrose to give a 200/
homogenate. The 9000g supernatant was
prepared by differential centrifugation.
Microsomes were obtained after addition of
CaCl2 (Schenkman & Cinti, 1972) and
resuspended in Earl's buffer. Different con-
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centrations ofNMF, up to 5mM, were incuba-
ted with liver preparations equivalent to
0 4 g liver/ml incubation medium (Earl's
buffer). The incubation mixtures wiere forti-
fied with 3mM MgCl2 and cofactors which
generated 1mM NADPH in a final volume
of 2-5 ml. The incubations were carried out
at 37°C, shaking for periods of up to 60 min
with access of air or 02.
IN VIVO metabolism.-The plasma profiles
for formamides were obtained after i.p.
administration of either 400 mg/kg NMF or
495 mg/kg NEF to male CBA/CA mice
(20-25 g). Blood was collected into heparin-
ized syringes by cardiac puncture, using a
mixture of NO, 02 and halothane as anaes-
thetic. Blood samples were centrifuged to
remove red blood cells and analysed. Urine
was collected from mice kept in mouse
metabowl cages (Jencons, U.K.).
Analytical methods and pharmacokinetic
analysis
In order to detect metabolically generated
formaldehyde, the incubation mixtures were
deproteinized with 0 5 ml of a 10% tri-
chloracetic acid (TCA) solution, centrifuged
and the supernatant used for the colori-
metric assay according to Nash (1953).
For the gas-chromatographic analysis,
samples of incubation mixtures, plasma or
urine, were diluted with 5 parts (plasma and
metabolic incubations) or 9 parts (urine)
acetone containing dimethylacetamide as
internal standard. After centrifugation the
supernatant was chromatographed in a Pye
Unicam 204 gas chromatograph fitted with
a selective nitrogen/phosphorus detector and
a glass column (2 m long, 4 mm i.d.) packed
with 100-120 mesh Chromosorb W17
WDMCS (Phase Separation Ltd., Clwyd)
coated with 8% Carbowax 2% KOH.
The following temperatures were applied:
injector 200°, column 190°, detector
250°C. Gas flow rates were 40 ml/min for
N2, 30 ml/min for H2 and 300 ml/min for
air. The limits ofsensitivity ofthe assay were
8.5 nmol/ml for NMF and NEF and 45
nmol/ml for formamide (F). The recovery of
these agents were 106+10% (NMF), 102+
6% (NEF) and 109+12% (F) in 6 deter-
minations. The area under the curve for
plasma NMF concentrationi vs time was
estimated by the trapezoid rule. The plasma
concentration values on the declining part
of the plasma-concentration vs time curve
(Fig. 5) were subjected to a linear regression
analysis which gave the apparent elimination-
rate constant. This was used for the calcula-
tion of the apparent elimination half-life.
Non-protein-thiol assay
Male BALB/c mice (20-25 g) with livers
weighing an average of 1 1 g were killed
between 8 and 10 a.m. One hour after drug
administration tissues were removed, blotted,
weighed and immediately homogenized in
5% TCA solution (5 ml/g liver). The pre-
parations were centrifuged at 2000 g for
10 min. Portions of the tissue supernatants
(150 ,ul for liver and 300 ,ul for the other
tissues) were diluted with 0-4M phosphate
buffer (pH 8.0) and 0 3 ml of OO1M 5,5'-
dithiobis-(2-nitrobenzoic acid) (DTNB) (Ell-
man, 1955) to give a final solution of 4 ml.
Samples were analysed in duplicate in a
Cecil CE 5095 spectrophotometer after 30
min at room temperature by reading the
absorbance at 412 nm against a blank
(sample without tissue homogenate). Gluta-
thione (GSH) standards in a 5% TCA
solution were assayed concurrently with
samples. The recovery of GSH was >90%
when added to the tissue samples.
RESULTS
Antitumour tests
The results for the in vivo antitumour
tests of various formamides against the
M5076 ovarian sarcoma, the S180 sarcoma
and the TLX5 lymphoma are shown in
Figs 1-4. The dosage schedule chosen for
the treatment of the M5076 and S180
sarcomas represents a treatment period
corresponding to approximately half the
life span of the control animals. The data
are presented to show tumour volumes
both during and after treatment in the
cases of the M5076 and S180 tumours.
The results for the in vitro-in vivo
assay which compares the cytotoxicities
of NMF, NEF and formamide are shown
in the Table. There is no significant
difference between the cytotoxicities of
these alkylformamides measured under
these conditions.
In a comparison of the antitumour
activity of 400 mg/kg NMF to both the
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FIG. 1.-Effect of various daily doses of NMF
over Days 1-17 on the growth of the DAY
M5076 ovarian sarcoma, expressed as a FIG. 3. Effect of various formamides (3(
percentage of the control tumour volumes mg/kg), given daily over Days 1-9, on tI
measured on the days indicated. = 6-25; growth of Sarcoma 180, expressed as
0 =12 5; A=25; A =50; 0=100; 0= percentage of the control tumour volum
200 mg/kg. measured on the days indicated. *
1 V12 1 6 20 24 28
DAY
FIG. 2.-Effect of various formamides (200
mg/kg) given daily over Days 1-17 on the
growth of the M5076 ovarian sarcoma,
expressed as a percentage of the control
tumour volumes measured on the days
indicated. *=formamide; F= NE;
0 = NMF.
TLX5S and TLX5R tumours, no signifi-
cant difference was observed in survival
time of the animals from either group,
suggesting that NMF is not cross-resistant
with procarbazine and dimethyl triazenes.
No detailed study was made here of the
toxicity of the formamides. In LD10
determinations using BALB/c mice, NMF
at a single i.p. dose had an LD10 of 800
mg/kg. In BDF1 mice, lethalities were
100 200 400 800
DOSE mg|kg
FIG. 4.-Effect of various formamides given
daily over Day 3-7 at different concentra-
tions (as shown) on the percentage increase
in survival time of animals bearing the
TLX5 lymphoma, when compared to
untreated animals. Key: * =formamide;
O =NEF; 0 =NMF.
obtained at 450 mg/kg NMF with the
Day 1-9 schedule, and at 300 mg/kg
with the Day 1-17 schedule. Weight loss
at 300 mg/kg over Days 1-17 was 2-9 g.
Further toxicological studies are in pro-
gress, and will be presented elsewhere.
Metabolism of N-alkylformamides
IN VITRO metabolism.-The results from
the in vitro-in vivo assay of NMF and
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TABLE.-Results of in vitro-in vivo bio-
assays of variousformamides using the
TLX5 lymphoma.
Compound
N-Methylformamide
(HCONHMe)
N-Ethylformamide
(HCONHEt)
Formamide
(HCONH2)
Concentration
(mM)
500
600
700
500
600
700
500
600
700
0 IST*
0
19
:36
38
t
53
0
4
6
* % IST=percentage increase in survival time of
animals receiving treated cells, compared to un-
treated controls.
t =3/5 animals survived > 200% of controls.
NEF (Table) suggested that their equi-
toxicity was nonspecific; since only NMF
was active against the TLX5 lymphoma
in vivo, NMF may be metabolized by the
host to a selective species which pre-
sumably was not formed by metabolism
of NEF. NMF was incubated with mouse
liver preparations (whole homogenate,
9000g supernatant and microsomes) with
and without 02, at varying substrate
concentrations and for varying incubation
periods. Oxidative N-demethylation, as
measured by the production of formalde-
hyde, was not detected by any of these
methods. Additionally, gas chromato-
graphic analysis showed no significant
disappearance of substrate or appearance
of formamide (F), the product of N-
demethylation.
IN VIVO metabolism and pharmaco-
kinetics.-Determination of plasma con-
centrations of NMF after administration
of the optimal antitumour dose (400
mg/kg) for the TLX5 lymphoma gave an
area under the plasma-concentration-time
curve of 62 ,umol.h/ml, and an apparent
plasma-elimination half-life of 3-6 h, as
determined by gas chromatography (Fig.
5). Formamide appeared in the plasma at
a peak concentration of 95 nmol/ml after
6 h; at other times the concentration of
formamide did not exceed the detection
limit.
N-alkylformamides and formamide
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FiG. 5. Disappearance of NMF from mouse
plasma after administration of 400 mg/kg
(6-8 mmol/kg). Experimental points are
the mean + s.d. of at least 4 experiments.
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IG. 6.-Amount of unchanged drug (A)
and of formamide (B) excreted in the urine
over 24 h after administration of 6-8
mmol/kg NMF or NEF. Results are the
means +s.d. of 6 experiments. For both
A and B, P < 0-05.
were detected in the urine of 6 animals
given either NMF or NEF (Fig. 6).
Within 24 h from the administration of
NMF 7-3 + 2.90% of the dose was excreted
as unchanged drug and 12 + 0.50/ as
formamide. Within 24 h after an equi-
molar dose of NEF 4*4 + 1.4% appeared
unchanged and 2-4 + 0 70/% as formamide.
r
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FIG. 7. Glutathione (GSH) levels in mouse
liver (top) and kidney (bottom) 1 h after
administration of various formamides,
proadifen (SKF 525-A) and proadifen
followed 1 h later by NMF. Numbers in
brackets refer to the number of determina-
tions and error bars are + s.d.
Effect of N-alkylformamides on soluble
non-protein thiols in liver.-The optimal
antitumour dose of NMF which had
minimal toxicity but a good anti-
tumour effect against the TLX5 lym-
phoma (400 mg/kg) caused a 59-8%
depletion of hepatic non-protein thiol
(NPT) in CBA mice measured 1 h after
administration. This depletion was not
brought about by NEF or formamide
(Fig. 7). Of the other tissues investigated
(heart, lungs, spleen and kidneys) only
the kidneys exhibited depletion, though
at 21.6% this was less marked than in
the liver. It thus appears that NMF
depletes the liver of the "labile" pool of
glutathione as defined by Higashi et al.
(1977) and which comprises 50-60% of
total NPT with a half life of 1-7 h. The
extent of hepatic NPT depletion was
dose-dependent (Fig. 8) and not abolished
by pretreatment with N-acetylcysteine.
However, pretreatment of the animals
with proadifen (SKF 525A, 60 mg/kg),
an inhibitor of hepatic mixed-function
oxidases (Cook et al., 1954), 1 h before
administration of NMF reduced the de-
pletion of hepatic NPT to 25.8% (Fig. 7).
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mg/kg
dose administered
FiG. 8. Dose-dependence of the fall in
hepatic glutathione (GSH) levels after
administration of NMF. Experimental
points are the mean + s.d. of at least 4
experiments.
]DISCUSSION
The results of the antitumour tests on
various formamides reported here (Figs
1-4) confirm previous findings regarding
structure-activity relationships for this
class of agent, namely, that only N-
methylformamide has significant activity,
though in some systems, but not the
TLX5 lymphoma (Fig. 4), formamide is
also active. The activity of NMF against
the ovarian sarcoma M5076 (Figs I & 2)
is an encouraging result, as this tumour
may be a good predictor of activity of
new compounds for the treatment of
human ovarian malignancies (Simpson-
Herren et al., 1979), though this has been
recently questioned (Slavik et al., 1981).
The equivalent cytotoxicity of both NMF
and NEF to TLX5S cells in vitro (Table)
contrasts with a clear difference of
potency in vivo, suggesting that this
in vitro toxicity is nonspecific, and
furthermore that NMF may possibly be
bioactivated to a product in vivo that is
either not formed from NEF or is formed
in insufficient quantities.
The interesting phenomenon that the
activity of certain antitumour compounds
containing an N-methyl group is greatly
reduced when substituted by an N-
ethyl group has been considered by us to
848
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be possibly due to differences in the
metabolic fate of the different N-alkyl
groupings (Hickman, 1978). Oxidative
N-dealkylation is a major pathway of
metabolism for N-alkyl-containing xeno-
biotics. In the case ofNMF, such biotrans-
formation should result in the production
of formamide and formaldehyde via an
intermediate carbinolamine, thus:
HCONH .CH3-HCONHCH20H-*
HCONH2+ HCHO
In the case of NEF, the products would
be expected to be formamide and acet-
aldehyde. The activity of formamide in
the in vivo antitumour tests reported
here migh-t suggest that the antitumour
activity of NMF is due to it acting as a
progenitoio of formamide. However, the
results with the TLX5kS lymphoma (Fig.
4 and Table) do not support this hypo-
thesis, as formamide has no activity, and
it is difficult to explain the very greatly
reduced potency of NEF, unless the
latter is not metabolized as much as
NMF.
Both NMF and NEF are metabolized
in vivo in the CBA mouse to what was
analytically detected as formamide in
urine (Fig. 6). Although the rates of
appearance of formamide differed, and
the amount detected represented a very
small proportion of the total dose, it is
felt unlikely that the difference in the
in vivo activity of NMF and NEF can be
attributed to the quantitative aspects of
metabolic formamide production. It is
possible that there are metabolic pathways
other than that suggested above for
N-alkylformamides. However, preliminary
experiments have shown that a stable
precursor of formaldehyde is indeed a
urinary metabolite of NMF, which sup-
ports the formation of the intermediate
carbinolamine metabolite postulated. This
will be the subject of a further report.
The disappearance of NMF from plasma
and the appearance of its metabolite
in urine indicate that host metabolism,
presumably via oxidative metabolism,
had occurred, but we were unable to
show any significant metabolism of this
type in vitro using various liver prepara-
tions. This contradicts the observations
of Barnes & Ranta (1972), who claimed
100% transformation of I-7 mM NMF
to formaldehyde after incubation with a
rat liver homogenate for 2 h. The level of
formaldehyde produced was, however,
close to the detection limit of the colori-
metric assay (Nash, 1953), and our
results show that incubation of liver
fractions for such long times leads to
significant levels of control absorbances
in the Nash assay, levels equivalent to
those found after incubation with NMF.
It is interesting that the structural
features required for anti-neoplastic acti-
vity of the formamides parallel those
found to deplete hepatic non-protein
thiols (NPT) (Fig. 7). The finding that
proadifen partly reversed the depletion
brought about by NMF strongly suggests
that metabolic oxidation of NMF pro-
duces a reactive metabolite capable of
reaction with soluble thiols. It has been
suggested that the effect of paracetamol
poisoning on the liver is due to an electro-
philic metabolite which depletes hepatic
glutathione stores and subsequently binds
covalently to hepatic macromolecules
which cause necrotic lesions (Mitchell
et al., 1972). By analogy, the hepatic
toxicity of NMF reported in the early
clinical trial (Myers et al., 1956) may be
related to the NPT depletion reported
here, and a reactive metabolite may also
be responsible for the antitumour effects
of NMF. Both of these hypotheses are
under active investigation by us.
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